A Review on the Novel Corona Virus with International and Indian Perspective
Abstract
On 31 December 2019, pneumonia of unknown cause was detected in Wuhan, China, and was first reported to the WHO Country Office in China. On 30 January 2020, the outbreak was declared a Public Health Emergency of International Concern. 1
It was an outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection that occurred in Wuhan, Hubei Province, China and got spread across China and beyond. WHO officially named the disease - Corona virus Disease 2019 (COVID-19) on February 12, 2020. 2
It has been spreading worldwide for a period of atleast a year & half 3 This review article addresses the current scenario caused by the SARS- Co V along with the treatment protocols and ongoing vaccines.
Keywords: Corona virus,COVID-19, m RNA, current therapy, vaccines, clinical symptoms, review
Keywords:
Corona virus, COVID-19, m RNA, current therapy, vaccines, clinical symptoms, reviewDOI
https://doi.org/10.22270/jddt.v11i4-S.4954References
WHO | Coronavirus disease (COVID-2019) R&D. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. Accessed April 1, 2020.
Zu ZY, Jiang M Di, Xu PP, et al. Pr e ss In Pr e. 2019;2019.
Morens DM, Daszak P, Taubenberger JK. Escaping Pandora ' s Box - Another Novel Coronavirus. 2020:1293-1295. https://doi.org/10.1056/NEJMp2002106
COVID-19 vs. Flu vs. Cold: Which One Do You Have? https://www.medicinenet.com/covid-19_vs_flu_vs_cold/article.htm. Accessed May 19, 2021.
Sriram N, Mondal TR, Reddy CM, Bagh SK. I nternational J ournal of A llied M edical S ciences and C linical R esearch ( IJAMSCR ) A review on novel Corona virus. 2020; 8(1):14-20.
Coronavirus disease (COVID-19): Similarities and differences with influenza. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza. Accessed May 19, 2021.
Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. doi:10.1093/nsr/nwaa036/5775463
Wu A, Peng Y, Huang B, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020; 27(3):325-328. doi:10.1016/j.chom.2020.02.001 https://doi.org/10.1016/j.chom.2020.02.001
Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect Dis Poverty. 2020; 9(1):1-12. doi:10.1186/s40249-020-00646-x https://doi.org/10.1186/s40249-020-00646-x
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing; 2020. http://www.ncbi.nlm.nih.gov/pubmed/32150360. Accessed April 11, 2020.
Fehr AR, Perlman S. HHS Public Access. 2016:1-23. doi:10.1007/978-1-4939-2438-7 https://doi.org/10.1007/978-1-4939-2438-7
Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjwjuqDBhAGEiwAdX2cj8RM6ZZ_t3yXvE4Ytt8QvYT4VYylOCvVMk1H9epi7-igjTB5DI69mhoCn_4QAvD_BwE. Accessed April 17, 2021.
Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol. 1990;64(11):5367-5375. doi:10.1128/jvi.64.11.5367-5375.1990 https://doi.org/10.1128/jvi.64.11.5367-5375.1990
Connell L. Library Guides: Harvard Referencing: Lecture notes.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. 2020. doi:10.1016/j.jaut.2020.102433 https://doi.org/10.1016/j.jaut.2020.102433
(No Title). 2020.
Elsevier Enhanced Reader. https://reader.elsevier.com/reader/sd/pii/S2452014421000492?token=7A54C695644DC2883E6C7F0ADA1E4722DD87D623E66BAFD1296E63F1FC4B33F2627A9DD4851B1A7B68545BA9CD69677D&originRegion=eu-west-1&originCreation=20210501032229. Accessed May 1, 2021.
Covid strain: Bangalore Corona samples show 11 mutations each; virus mutating faster than before | India News - Times of India. https://timesofindia.indiatimes.com/india/covid-bluru-samples-show-11-mutations-each-virus-mutating-faster-than-before/articleshow/81333377.cms. Accessed May 1, 2021.
Inside the COVID-19 mutant: The 'drift' of a virus. https://www.businesstoday.in/bt-buzz/news/inside-the-covid-19-mutant-the-drift-of-a-virus/story/425695.html. Accessed May 1, 2021.
New Covid strain in Singapore: What we know so far about B.1.617 variant affecting children. https://www.livemint.com/science/health/new-covid-strain-in-singapore-what-we-know-so-far-about-b-1-617-variant-affecting-children-11621358293334.html. Accessed May 25, 2021.
Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021; 595(7865):17-18. doi:10.1038/D41586-021-01696-3 https://doi.org/10.1038/d41586-021-01696-3
Vaccines highly effective against B.1.617.2 variant after 2 doses - GOV.UK. https://www.gov.uk/government/news/vaccines-highly-effective-against-b-1-617-2-variant-after-2-doses. Accessed July 7, 2021.
Bhatnagar T, Murhekar M, Soneja M, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J Med Res. 2020; 0(0):0. doi:10.4103/ijmr.IJMR_502_20 https://doi.org/10.4103/ijmr.IJMR_502_20
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. doi:10.1056/NEJMoa2001282 https://doi.org/10.1056/NEJMoa2001282
Valentin F, Gurabo R. Lopinavir / Ritonavir and COVID-19. 2020; (April). doi:10.13140/RG.2.2.14844.69767
Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study - Reuters. https://in.reuters.com/article/health-coronavirus-roche-hldg/roche-rheumatoid-arthritis-drug-fails-to-help-covid-19-patients-in-italian-study-idINKBN23P1WM. Accessed July 30, 2020.
What's new | Coronavirus Disease COVID-19. https://www.covid19treatmentguidelines.nih.gov/whats-new/. Accessed July 30, 2020.
Gupta AK, Parker BM, Priyadarshi V, Parker J. Cardiac Adverse Events With Remdesivir in COVID-19 Infection. Cureus. 2020; 12(10). doi:10.7759/cureus.11132 https://doi.org/10.7759/cureus.11132
Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip. 2020; 34(1):469-474. doi:10.1080/13102818.2020.1775118 https://doi.org/10.1080/13102818.2020.1775118
Velavan TP, Meyer CG. The COVID-19 epidemic. 2020; 25(3):278-280. doi:10.1111/tmi.13383 https://doi.org/10.1111/tmi.13383
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study | pfpfizeruscom. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious. Accessed April 17, 2021.
Moderna COVID-19 Vaccine Overview and Safety | CDC. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html. Accessed April 17, 2021.
Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv. December 2020. doi:10.1101/2020.12.21.20248643 https://doi.org/10.1101/2020.12.21.20248643
Johnson & Johnson's Janssen COVID-19 Vaccine Overview and Safety | CDC. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html. Accessed April 17, 2021.
Evaluation of COVID-19 vaccine effectiveness. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1. Accessed May 16, 2021.
What Are the Complications of Coronavirus (COVID-19)? https://www.webmd.com/lung/coronavirus-complications#1. Accessed May 25, 2021.
Certain Medical Conditions and Risk for Severe COVID-19 Illness | CDC. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed May 25, 2021
Published
Abstract Display: 605 
PDF Downloads: 574 PDF Downloads: 59 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.